Blog
RSS FeedPosted by Michael Wonder on 17 Jul 2019
Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund
17 July 2019 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...
Posted by Michael Wonder on 10 Jul 2019
Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage
9 July 2019 - A unit of Novartis said on Tuesday it would make partner Adamis Pharmaceuticals Corp’s emergency allergy ...
Posted by Michael Wonder on 10 Jul 2019
ICER's final report on peanut allergy treatments: clinical evidence does not yet demonstrate that long-term benefits of desensitisation outweigh short-term risks
10 July 2019 - Independent appraisal committee highlights importance of non-clinical benefits and contextual considerations when evaluating AR101 and Viaskin Peanut. ...
Posted by Michael Wonder on 10 Jul 2019
Amazon’s Alexa to offer NHS health care advice
10 July 2019 - The UK Government has announced that the NHS has plans to collaborate with Amazon to provide ...
Posted by Michael Wonder on 10 Jul 2019
FDA approves Katerzia, the first and only amlodipine oral suspension for paediatric patients 6 years of age and older
10 July 2019 - Azurity Pharmaceuticals announced today that the U.S. FDA has approved Katerzia (amlodipine) 1 mg/mL oral suspension, ...
Posted by Michael Wonder on 10 Jul 2019
FDA to review isatuximab as a potential treatment for relapsed/refractory multiple myeloma
10 July 2019 - The U.S. FDA has accepted for review the biologics license application for isatuximab for the treatment ...
Posted by Michael Wonder on 10 Jul 2019
Why disclosing drug prices in TV ads won't lower costs
10 July 2019 - A federal judge blocked President Donald Trump’s order to force drugmakers to disclose the list prices ...
Posted by Michael Wonder on 10 Jul 2019
Drug makers boost prices up to 909%, defying political pressure
10 July 2019 - Bipartisan efforts to lower drug prices in Washington have not prevented drugmakers from going about their ...
Posted by Michael Wonder on 10 Jul 2019
Cellectar receives FDA fast track designation for CLR 131 in diffuse large B-cell lymphoma
9 July 2019 - Cellectar Biosciences today announced the U.S. FDA has granted fast track designation for CLR 131 in relapsed ...
Posted by Michael Wonder on 10 Jul 2019
Vaccine crisis leaves Australia’s immunisation record in tatters
9 July 2019 - Thousands of Australians are dying from the flu and meningococcal because lifesaving vaccines are not being approved, ...
Posted by Michael Wonder on 09 Jul 2019
CMS’s international pricing model for Medicare Part B drugs: implementation issues
9 July 2019 - For many years, Americans have paid significantly more than the rest of the world for prescription drugs. ...
Posted by Michael Wonder on 09 Jul 2019
'Amazing' gene-silencing drugs reach NHS
9 July 2019 - A new form of medicine called "gene-silencing" has been approved for use by the NHS in ...
Posted by Michael Wonder on 09 Jul 2019
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice
9 July 2019 - The long-acting injectable regimen has been granted priority review status by the FDA, with a target approval ...
Posted by Michael Wonder on 09 Jul 2019
GSK welcomes the UK trial of subscription-style payment system for pharma companies to incentivise creation of new antibiotics
9 July 2019 - GSK is committed to tackling antimicrobial resistance as part of a sustained, multi-stakeholder response to this global ...
Posted by Michael Wonder on 09 Jul 2019
FDA accepts Merck’s supplemental biologics license applications for Keytruda (pembrolizumab) six-week dosing schedule for melanoma and multiple other indications
9 July 2019 - Merck today announced that the U.S. FDA has accepted for review six supplemental biologics license applications to ...
Posted by Michael Wonder on 09 Jul 2019
FDA leverages private sector technology-based tools in its embrace of real world evidence
9 July 2019 - Following decades of near total reliance on randomised clinical trial data, the U.S. FDA (with a ...